Clinical trial · Interventional
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer
Phase I Study of Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer
NCT03236883CI-TRIAL-00028905HSTunknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the safety and efficacy of non-myeloablative hematopoietic stem cell transplantation in the treatment of pancreatic cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer Stage III | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
| Pancreatic Cancer Stage IV | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gemcitabine | Drug | Gemcitabine | ALIAS |
| GPBSC | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- GEM plus GPBSC
- description
- Gemcitabine chemotherapy with mobilized GPBSC infusion:Gemcitabine 1000mg/m2 +GPBSC(2-3)\*10\^8/kg
- interventionNames
- Drug: Gemcitabine
- Other: GPBSC
- type
- OTHER
- label
- Gemcitabine
- interventionNames
- Drug: Gemcitabine
- type
- OTHER
- label
- GPBSC
- interventionNames
- Other: GPBSC
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * PET-CT/EUS-FNA cytologically confirmed stage III -Ⅳ of pancreatic cancer * Between 18 and 80 years old * Karnofsky Performance Status (KPS) ≥ 70%,Guaranteed treatment for 3 months * Normal functions of heart, lung and kidney * Adequate hematological profile: Hemoglobin ≥ 9.0 g/dL、 Absolute granulocyte count ≥ 1,500/mm\^3 、Platelet count ≥ 100,000/mm\^3, start the treatment within 14 days after these results meet the requirements * A life expectancy \> 3 months * Informed consent signed * HLA-haplotype-matched immediate family health donors who have been confirmed by laboratory HLA genotypes * Interval the last anti-tumor treatment for more than 3 months Exclusion Criteria: * Highly allergic or people with severe allergies * Brain metastasis or Primary central nervous system malignancy * Suffer from clinical illnesses that affect clinical trials, including but not limited to: Uncontrollable diabetes;active infectious disease or uncontrollable infection; acute and chronic liver disease; confirmation of HIV infection; uncontrollable hypertension, symptomatic congestive heart-failure, unstable angina pectoris, and myocardial infarction, uncontrollable arrhythmia over the last 6 months. * Combined heart, lung, kidney and other vital organs dysfunction * A serious coagulation dysfunction, a clear history of other tumors * Pregnant and lactating women * Mental illness, affecting the compliance of clinical trials * The patient will participate in other trials within 10 days prior to the trial or While participating in other tests * Patients underwent weight loss by 10% and above within 6 weeks before the start of the trial * Neutrophils\<500mm\^3 or Platelet count\<50,000/mm\^3 * Need to drive and manipulate the machine during the trial Donor's Inclusion Criteria: * First-degree relatives of patients * Age\<55 years old * Normal functions of heart, lung and kidney * Adequate hematological profile: Hemoglobin ≥ 9.0 g/dL、 Absolute granulocyte count ≥ 1,500/mm\^3 、Platelet count ≥ 100,000/mm\^3、WBC≥ 3000/mm\^3, start collecting stem cells within 14 days after these results meet the requirements * Informed consent signed Donor's exclusion Criteria: * Highly allergic or people with severe allergies * The person who have history of atherosclerosis, venous thrombosis or autoimmune disease * A serious coagulation dysfunction, a clear history of other tumors * Infectious disease or carriers * Pregnant and lactating women * Mental illness, affecting the compliance of clinical trials * WBC\<4000/mm\^3、PLT\<70\*10\^9/L
References
Publications (0)
Data not yet available
No reference posted for this study.